Wensor et al., 1998
Its frustrating when your efforts to lose weight dont pay off
Next-generation agents include CagriSema (semaglutide + cagrilintide, NDA filed December 2025, showing 22.7% weight loss), retatrutide (triple GIP/GLP-1/glucagon agonist, 28.7% weight loss in Phase 3), and orforglipron (oral non-peptide GLP-1, submitted to FDA)
Danish and his team at Philadelphia Integrative Psychiatry develop for their patients
Ahead, Hinge Health physical therapists explain how combining medications like Ozempic with exercise , eating enough protein, and making other lifestyle changes can help you adjust to (and manage) these cosmetic changes in your feet
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association